AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Dostarlimab/chemotherapy elicited a 31% decrease in the risk of death compared with placebo/chemotherapy in locally advanced/recurrent endometrial cancer.
Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care
Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.
Psilocybin May Help Address Cancer-Related Psychological Concerns
Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.
Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Tisotumab Vedotin Improves Survival in Cervical Cancer Subpopulation
Progression-free survival and objective response rate outcomes favored the tisotumab vedotin arm in the China subpopulation of the innovaTV 301 study.
FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS
The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.
UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer
UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.
Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC
A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.
Advancement of First-Line Treatments on EGFR-Mutated NSCLC
As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.
NSCLC Experts Ponder Best First-Line Treatment Options
The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.
University of Chicago Thought Process on First-line Treatment in EGFR NSCLC
Referring to the NCCN guidelines for the treatment of EGFR-mutated NSCLC will help clinicians determine which treatments are best recommended.
Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC
The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.
Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies
Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.
OST-HER2 Significantly Prevents Recurrent Lung Metastatic Osteosarcoma
Interim analysis data show improvements in overall survival with OST-HER2 in this osteosarcoma population compared with historical controls.
FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
Acalabrutinib Plus Chemotherapy Provides Cover for High-Risk Patients in MCL
“Some of the early data that came out of the [ECHO] trial that led to this approval does suggest that it may be beneficial in some high-risk patients,” Tycel Phillips, MD, said.
FDA Issues CRL for Tabelecleucel in EBV+ Lymphoproliferative Disease
The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.
Durvalumab Plus Bevacizumab Improves PFS Outcomes in Unresectable HCC
Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.
Brentuximab Vedotin Combination Improves Survival in Pretreated R/R DLBCL
Brentuximab vedotin, lenalidomide, and rituximab yielded a median OS of 13.8 months and a median PFS of 4.2 months in the phase 3 ECHELON-3 trial.
FDA Approves Sotorasib/Panitumumab in KRAS G12C-Mutated CRC
Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.
FDA Approves Acalabrutinib Combo in Previously Untreated MCL
The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.
Moving Novel Brain Cancer Treatment Classes Down the Development Pipeline
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma
Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD
The developers expect the product to be available for order in the United States in early February 2025.
TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer
Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.
Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Performing Timely Testing in Novel Brain Cancer Therapy Development
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
FDA Receives NDA for TAR-200 in BCG-Unresponsive High-Risk NMIBC
Data from the phase 2b SunRISe-1 study support the NDA for TAR-200 in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer with CIS.
